Sign-up here for the COBO-Q Newsletter and receive the latest updates within Quality Control Genome Editing.
New CRISPR gene editing clinical studies are rapidly emerging, now with more than 45 ongoing clinical trials including CRISPR, ZFNs, TALENs or MegaNucleases. Check the latest updates from CRISPR Medicine News.
Read interview with CSO, Kiana Aran from Cardea Bio - US-based partner to COBO Technologies
PIPPR Pathway Analysis Framework used for Proteome Analysis of SARS-CoV-2 Infected Cells
Cobo Technologies PIPPR® platform has been specifically designed to understand, at the proteome level, the changes caused by CRISPR genetic editing of cell lines, whether of animal or plant origin.
The CRISPR Medicine News site has launched the worlds first overview of ongoing clinical trials within the genome editing field. This overview will include any trials from Asia, US and Europe, where genome editing tools like CRISPR, ZFNs, TALENs and MegaNucleases have been used.
Re-analysis of SARS-CoV-2 infected host cell proteomics time-course data by impact pathway analysis and network analysis. A potential link with inflammatory response
The RAW 264.7 PIPPR Signature Library is created using PIPPR - Proteome Expression analysis Platform (powered by MS-SWATH). Go into the details of the proteome expression in your next CRISPR experiment.
The partners have agreed to co-develop and market a portfolio of CRISPR QC products and services for quality control (QC) of CRISPR research, agricultural, and pre-clinical programs.
Development is moving fast in the genome editing field and new applications are launched every quarter but do we really understand the level of complexity in genome editing and how to address quality and safety?
It´s at the Precision Medicine World Conference, PMWC2020 and it´s all about QC Genome Editing, CRISPR InDel profiling and Proteomic analysis powered by SWATH Acquisition.
Taking CRISPR Safety to the Next Level - "If we want to move to the clinic, we need to understand exactly what is going on inside the cells when we apply CRISPR "....
The HEK293 PIPPR Signature Library is created using PIPPR - Proteome Expression analysis Platform (powered by MS-SWATH). Go into the details of the proteome expression in your next CRISPR experiment.
The CRISPR Medicine Blog focus on topics related to gene therapy and genome editing using CRISPR (or other nucleases) for treatment of human diseases.
PIPPR - Fast, robust and cost-effective proteomic screening platform - powered by SWATH and developed for CRISPR applications.
Finally we can share with you the FAQ site for our CRISPR InDel Profiling Platform, CIPP - powered by IDAA.
The NIST Genome Editing Consortium seeks feedback on terms and definitions specific to genome editing.
SCIEX Seminar in Copenhagen, Denmark 3rd October 2019.
To support our Proteomic Expression analysis Platform, PIPPR, we are excited to launch the PIPPR Total Mammalian Protein Extraction kit
We are excited to announce our new partnership with SCIEX for our proteomic expression analysis platform, PIPPR powered by SWATH LC-MS.
We are excited to launch COBO-Q - the first newsletter with focus on news and updates within Quality Control Genome Editing.
We are happy to share with you the launch of the powerful PROFILase 2x Master Mix - optimised for INDEL analysis using the IDAA method.
In the News
"Keep an eye on our Network Member, the Danish biotech company Cobo Technologies - potential to influence future drug development"
Great presentation by Roberto Nitsch, Safety Director, AstraZeneca at the NIST - Genome Editing Consortium Workshop 3rd May 2019 in US, on the idea behind their PIPPR project to understand the impact of CRISPR Base-Editors (ABE) on proteomic level.
We are looking forward to meet all the members of the NIST - Genome Editing Consortium in US May 3rd. Our Co-founder and Scientific Advisor, Eric Paul Bennett and COO, Hasse Herlevsen will attend.
To further strengthen our expertise within the Quality Control field, Hasse Herlevsen (former Corp. VP Quality, LEO Pharma) will join our team as COO.
We are excited to announce that we have become member of the NIST - Genome Editing Consortium in US.
Finally we can share with you all our new website - www.cobotechnologies.com.